Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;29(4):540-552.
doi: 10.5603/CJ.a2022.0026. Epub 2022 May 6.

Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022

Jacek Kubica  1 , Piotr Adamski  2 , Jerzy R Ładny  3 , Jarosław Kaźmierczak  4 , Tomasz Fabiszak  1 , Krzysztof J Filipiak  5 , Robert Gajda  6 , Mariusz Gąsior  7 , Zbigniew Gąsior  8 , Robert Gil  9 , Jarosław Gorący  10   4 , Stefan Grajek  11 , Leszek Gromadziński  12 , Marcin Gruchała  13 , Grzegorz Grześk  14 , Piotr Hoffman  15 , Miłosz J Jaguszewski  16 , Marianna Janion  17 , Piotr Jankowski  18   19 , Zbigniew Kalarus  20 , Jarosław D Kasprzak  21 , Andrzej Kleinrok  22 , Wacław Kochman  23 , Aldona Kubica  1 , Wiktor Kuliczkowski  24 , Jacek Legutko  25 , Maciej Lesiak  11 , Klaudiusz Nadolny  26 , Eliano P Navarese  1 , Piotr Niezgoda  1 , Małgorzata Ostrowska  1 , Przemysław Paciorek  1 , Jolanta Siller-Matula  27   28 , Łukasz Szarpak  29   30 , Dariusz Timler  31 , Adam Witkowski  32 , Wojciech Wojakowski  33 , Andrzej Wysokiński  34 , Marzenna Zielińska  35
Affiliations

Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022

Jacek Kubica et al. Cardiol J. 2022.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Jacek Kubica: lecture fees from AstraZeneca, Bayer; Piotr Adamski: none; Jerzy R. Ładny: none; Jarosław Kaźmierczak: none; Tomasz Fabiszak: none; Krzysztof J. Filipiak: lecture fees from Adamed, AstraZeneca, Sanofi Aventis; Robert Gajda: none; Mariusz Gąsior: lecture fees from AstraZeneca; Zbigniew Gąsior: none; Robert Gil: none; Jarosław Gorący: lecture fees from Astra-Zeneca; Stefan Grajek: none; Leszek Gromadziński: none; Marcin Gruchała: none; Grzegorz Grześk: none; Piotr Hoffman: none; Miłosz J. Jaguszewski: speaking fees and travel grants from: Boheringer Ingelheim, Bayer, AstraZeneca, and Pfizer outside the submitted work; Marianna Janion: none; Piotr Jankowski: lecture fees, conference and scientific grants from Amgen, Boehringer Ingelheim, KRKA, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Teva, Zentiva; Zbigniew Kalarus: none; Jarosław D. Kasprzak: lecture fees from Aflofarm, Polpharma, AstraZeneca, research grants from Aflofarm; Andrzej Kleinrok: none; Wacław Kochman: none; Aldona Kubica: none; Wiktor Kuliczkowski: none; Jacek Legutko: lecture fees from AstraZeneca, Berlin-Chemie Menarini, Gedeon Richter; Maciej Lesiak: lecture fees from AstraZeneca, Gedeon Richter; Klaudiusz Nadolny: none; Eliano P. Navarese: none; Piotr Niezgoda: none; Małgorzata Ostrowska: none; Przemysław Paciorek: none; Jolanta Siller-Matula: none; Łukasz Szarpak: none; Dariusz Timler: none; Adam Witkowski: lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer; Wojciech Wojakowski: lecture fees from Astra-Zeneca, Pfizer, Boehringer Ingelheim; Andrzej Wysokiński: none; Marzenna Zielińska: none.

Figures

Figure 1
Figure 1
Algorithm for pre-hospital management of acute coronary syndromes (ACS); ASA — acetylsalicylic acid; ECG — electrocardiography; LD — loading dose; NSTE-ACS — non-ST-segment elevation acute coronary syndrome; PCI — percutaneous coronary intervention; SaO2 — saturation of oxygen; STEMI — ST-segment elevation myocardial infarction; UFH — unfractionated heparin.
See this image and copyright information in PMC

References

    1. Kubica J, Adamski P, Paciorek P, et al. Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts’ standpoint. Kardiol Pol. 2017;75(4):399–408. doi: 10.5603/KP.a2017.0057. - DOI - PubMed
    1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393. - DOI - PubMed
    1. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
    1. Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint. Cardiol J. 2018;25(3):291–300. doi: 10.5603/CJ.a2018.0042. - DOI - PubMed
    1. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575. - DOI - PubMed